Canalys:中國首季智能手機出貨量跌18% 榮耀首登頂
調查機構Canalys發表的研究報告指,第一季中國智能手機市場出貨量爲7,560萬臺,按年下跌18%。
當中,榮耀以1,500萬臺的出貨量和205%的增長率首次登頂。OPPO(包括OnePlus)在持續品牌轉型下,以1,390萬臺的出貨量保持第二位。蘋果(AAPL.US)在去年第四季度的強勁表現後,繼續位居在第三位。Vivo和小米(01810.HK)躋身前五,出貨量分別爲1,220萬臺和1,060萬臺。
Canalys分析師Amber Liu指,隨着華爲在最近幾個季度的淡出,前五大供應商之間的競爭一直非常激烈。而榮耀在線下渠道持續增長,新的60和X30系列亦爲穩健的表現做出貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.